TTFields; rationale is fascinating. LUNAR trial n276; mOS HR 0.74. #ASCO23 #LCSM

1ª intervención de Delvys Rodriguez Abreu en #ASCO23 . Excellent discussion, congrats!!🚀🫁
“Baseline autoantibody profiling in patients with #NSCLC with pre-existing autoimmune diseases ir who had received prior anti-PD-1 therapy before enrolling in the TAIL study” #lungresearch #LCSM

The DEA has released guidance on the new one-time requirement for 8 hours of training on the treatment & management of patients with opioid or other substance use disorders. #ASAM offers a variety of education that meets the needs of all prescribers >> ow.ly/bUu350Nu1rO

On my way to #asco23 to learn more about #lungcancer so I can help other survivors and myself. I've had 3 brain radiations and 5! brain surgeries since my last one (2019). #lcsm #diecancerdie

Voy a ver a Taylor lcsm

ADAURA; look at NEJM supplementary ; 7% 5y landmark advantage for those who got adjuvant chemo. My view will be to recommend adjuvant chemo before adjuvant osimertinib #ASCO23 #LCSM

Thank you Marina for an unforgettable evening Thank Lung Friends! Marina Garassino #LCSM

Don’t miss my lecture during the PER symposium on multidisciplinary care for patients with EGFR mutation-positive NSCLC at the annual oncology meeting in Chicago on June 4! Sign up today! bit.ly/3Wx2FDp #lcsm #gotoPER

Vamos talleres lcsm 💙 🇫🇮

Reds, get your official LFC Nike 23/24 Home Kit in-store, online and on the LFC store app 🔴

Running into RutgersCancerInstNJ colleagues in between presentations at #ASCO23 #lcsm #gyncsm #bcsm Eugenia Girda, MD Missak Haigentz

Although I have a tiny bit of FOMO from missing #ASCO23 , seeing my older son graduate from college nearly 10 years after being diagnosed with stage IV EGFR+ #lungcancer is well worth it! #lcsm EGFR Resisters Princeton University Princeton Alumni Jyoti D Patel Lurie Cancer Center Northwestern Medicine

Outstanding discussion done by Dr. Joshua Sabari who dissected all data from KRASG12C plus chemo, data on JDQ443 novel inh and the biomaker analysis from CodeBreak 200. I rec to watch this presentatio again. Joshua Sabari, MD IASLC ASCO #ASCO2023 FLASCO Ferdinandos Skoulidis KRASKickers

Now presenting our work on PD-L1 and TMB variations in #NSCLC #LCSM ASCO ASCOPost
Stop by for a chat!

Abstract 9126: Subcutaneous amivantamab in patients with advanced solid tumors: The PALOMA study by Anna Minchom. IRRs were reported in 16% without grade 3 or more. PK analysis confirmed that ami SC 1600 mg Q2W shows similar exposure to the IV dose (1050 mg Q2W). #ASCO23 #LCSM

EAST ENERGY : 2# neoadj Pembro+ram in PDL1+ ELC; n=24; MPR and pCR high. 2/24 not operated. Interesting chemo free neoadj strategy. #ASCO23 #LCSM

Still here at #ASCO23 listening to last day of #lungcancer presentations. #lcsm

Way to go Joshua Sabari, MD! #LCSM

As biomarkers become more utilized in a variety of cancers, let's highlight current biomarker patient groups. They have a wealth of lived experience. #ASCO23 #LCSM